UPC_APP_17607/2025

RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Procedural & sub-applicationsWithdrawal ApplicationsMilan CDApplication Rop 265—Settled at: Pre-merits

Overview Decisions Documents Timeline

Parties

Claimants

Pfizer, Inc.
Pfizer Europe MA EEIG
Pfizer B.V.
Pfizer S.A.
Pfizer Manufacturing Belgium S.A.
Pfizer Service Company S.R.L.
Pfizer Pharma GmbH
Pfizer Limited

Reps: Gareth Williams

Respondents

GlaxoSmithKline Biologicals SA

Reps: Oliver Jan Juengst; Daniela Kinkeldey

Judges

Andrea PostiglionePresiding Judge
Anna-Lena KleinJudge-rapporteur
Steen Lyders Wadskov-HansenTechnically Qualified Judge

Patents

EP4183412

CPC codes: C12N2760/18522, C12N2760/18534, A61K2039/55505, A61K2039/5258, A61K2039/55566, A61K39/155, A61K39/12, C07K2319/73, A61K2039/53, C07K2317/76, A61P31/14, A61P37/04…

Sector: Biotechnology

Outcome

Withdrawn

Filed: —

First decided: Apr 22, 2025

Language: —

Settled at: Pre-merits

The Milan Central Division allowed Pfizer's withdrawal of both the revocation action (ACT_45928/2024) and the counterclaim for revocation (CC_60908/2024) against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV vaccine patent), with GSK's consent and without a cost decision; 60% of court fees were reimbursed to Pfizer.